Melanoma News

January 18, 2025January 18, 2025

Monocentric Study on the Clinical and Ultrasound Incidence of Rheumathologic Immune Related Adverse Events in Patients Affected by Stage IIB, IIC, III and IV Melanoma Under Therapy With Immune-checkpoint Inhibitors

Melanoma News

Publication date: Jan 13, 2025 Rheumatologic adverse events are expected to affect between 3% and 7. 5% of patients undergoing immunotherapy and are likely to be underdiagnosed. The main aim ... Read more

January 18, 2025January 18, 2025

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

Melanoma News

Publication date: Jan 13, 2025 This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase ... Read more

January 18, 2025January 18, 2025

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator’s Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Melanoma News

Publication date: Jan 16, 2025 This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment ... Read more

January 18, 2025January 18, 2025

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

Melanoma News

Publication date: Jan 16, 2025 BRAF inhibitor-resistant melanomas (BRAFiR) acquire (epi)genetic and functional alterations that enable them to evade alternative treatments. Identifying these alterations is critical to advancing treatment strategies. ... Read more

January 17, 2025January 17, 2025

Evaxion concludes subject dosing in Phase II trial of melanoma vaccine

Melanoma News

Publication date: Jan 17, 2025 “Evaxion concludes subject dosing in Phase II trial of melanoma vaccine” was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The ... Read more

January 15, 2025January 15, 2025

Diabetes Drug Protects Against Skin Cancer, New Research Says

Melanoma News

Publication date: Jan 15, 2025 Of those, 8 out of 10 are basal cell cancers. Deaths from these skin cancers are not common. Concepts Keywords Cancer Basal Reporterhealthdaytuesday Cancer Sunprotected ... Read more

January 12, 2025January 12, 2025

Possible relation between HLA and ABO type and prognosis of uveal melanoma

Melanoma News

Publication date: Jan 10, 2025 We conclude that the HLA type of the patient may influence the clinical behavior not only of skin melanoma but also of uveal melanoma. We ... Read more

January 12, 2025January 12, 2025

Innovative Porcine Model Developed To Study Melanoma – The Pinnacle Gazette

Melanoma News

Publication date: Jan 11, 2025 Researchers have successfully developed a genetically engineered porcine model to study melanoma, leveraging the conditional expression of specific oncogenes to mimic human disease more closely ... Read more

January 12, 2025January 12, 2025

Recurrence, mortality rates better in nevus-associated vs. de novo acral melanoma

Melanoma News

Publication date: Jan 12, 2025 Nevus-associated acral melanoma (NAAM) was present in 34% of patients and de novo acral melanoma (DNAM) was diagnosed in 66%. However, the biological mechanisms behind ... Read more

January 11, 2025January 11, 2025

Dr Dronca on the FDA Approval of Subcutaneous Nivolumab in Solid Tumors – OncLive

Melanoma News

Publication date: Jan 09, 2025 “Subcutaneous the approval of subcutaneous nivolumab really represents a shift, especially for solid tumors, in how cancer treatments are delivered and conceptualized. The approval of ... Read more